XML 49 R20.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Tax Disclosure [Abstract] |
Income Taxes | Income Taxes The components of loss before income taxes for the following years ended December 31, are as follows:
Loss Before Income Taxes: |  | 2024 |  | 2023 |  | 2022
Europe |  | $ | (3,708) |  |  | $ | (45,835) |  |  | $ | (53,684) |
U.S. |  | (45,371) |  |  | (114,942) |  |  | (57,755) |
Total loss before income taxes |  | $ | (49,079) |  |  | $ | (160,777) |  |  | $ | (111,439) |
The income tax (benefit) provision consists of the following for the years ended December 31:
Income Tax (Benefit) Provision: |  | 2024 |  | 2023 |  | 2022
Current: |  |  |  |  |  |
U.S. - State |  | $ | — |  |  | $ | (661) |  |  | $ | — |
Total current |  | — |  |  | (661) |  |  | — |
Deferred: |  |  |  |  |  |
U.S. - Federal |  | — |  |  | — |  |  | 25,896 |
U.S. - State |  | (247) |  |  | 160 |  |  | 129 |
Total deferred |  | (247) |  |  | 160 |  |  | 26,025 |
Income tax (benefit) provision |  | $ | (247) |  |  | $ | (501) |  |  | $ | 26,025 |
The reconciliation between income taxes at the statutory rate and the Company’s (benefit) provision for income taxes is as follows for the following years ended December 31:
Reconciliation to Effective Income Tax Rate: |  | 2024 |  | 2023 |  | 2022
Income tax (benefit) provision - at statutory tax rate |  | $ | (6,135) |  |  | $ | (20,097) |  |  | $ | (13,916) |
Differences in international tax rates |  | (2,991) |  |  | (6,635) |  |  | (9,921) |
Return to Provision |  | 2,632 |  |  | 856 |  |  | (101) |
Change in valuation allowances |  | 4,982 |  |  | 24,332 |  |  | 48,734 |
Nondeductible share-based compensation |  | 1,444 |  |  | 798 |  |  | 1,424 |
Unrealized tax benefits |  | (218) |  |  | 160 |  |  | 258 |
State and local taxes (net of federal) |  | 778 |  |  | (5,614) |  |  | (4,467) |
Nondeductible interest expense |  | (848) |  |  | 4,362 |  |  | 4,239 |
Orphan drug and R&D tax credit |  | (30) |  |  | 899 |  |  | — |
Other |  | 139 |  |  | 438 |  |  | (225) |
Income tax (benefit) provision - at effective income tax rate |  | $ | (247) |  |  | $ | (501) |  |  | $ | 26,025 |
In 2024, the income tax benefit was $247, a decrease of $254 from income tax benefit of $501. The change in the effective tax rate for the year ended December 31, 2024 is primarily driven by the reversal of unrecognized tax benefits during the year. The effective tax rate for 2022 was impacted by the valuation allowance. Unrecognized Tax Benefits The Company or one of its subsidiaries files income tax returns in Ireland, France, U.S. and various states. The Company is no longer subject to Irish, French, U.S. Federal, and state and local examinations for years before 2020. The following table summarizes the activity related to the Company’s unrecognized tax benefits for the years ended December 31:
Unrecognized Tax Benefit Activity |  | 2024 |  | 2023 |  | 2022
Balance at January 1: |  | $ | 3,035 |  |  | $ | 3,143 |  |  | $ | 3,143 |
Increases for tax positions of prior years |  | — |  |  | — |  |  | — |
Statute of limitations expiration |  | (311) |  |  | (108) |  |  | — |
Settlements |  | — |  |  | — |  |  | — |
Balance at December 31: |  | $ | 2,724 |  |  | $ | 3,035 |  |  | $ | 3,143 |
The Company expects that within the next twelve months the unrecognized tax benefits could decrease by approximately $1,637 and the interest could increase by an immaterial amount. At December 31, 2024, 2023 and 2022, there are $2,724, $3,035,and $3,143 of unrecognized tax benefits that if recognized would affect the annual effective tax rate. The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax provision. During the years ended December 31, 2024, 2023 and 2022, the Company recognized approximately $56, $268 and $258 in interest and penalties, respectively. The Company had approximately $2,427 and $2,372 for the payment of interest and penalties accrued at December 31, 2024 and 2023, respectively. Deferred Tax Assets (Liabilities) Deferred income tax provisions reflect the effect of temporary differences between consolidated financial statement and tax reporting of income and expense items. The net deferred tax assets (liabilities) at December 31, 2024 and 2023 resulted from the following temporary differences:
Net Deferred Tax Assets and Liabilities: |  | 2024 |  | 2023
Deferred tax assets: |  |  |  |
Net operating loss carryforwards |  | $ | 68,568 |  |  | $ | 71,051 |
Share-based compensation |  | 9,791 |  |  | 7,347 |
Royalty income |  | 9,334 |  |  | 8,378 |
Reserves and Other Accruals |  | 4,603 |  |  | — |
Orphan drug and R&D tax credit |  | 4,095 |  |  | 4,065 |
Capitalized research costs |  | 1,568 |  |  | 1,738 |
Interest expense carryforward |  | 1,460 |  |  | 1,368 |
Other |  | 1,176 |  |  | 1,322 |
Amortization |  | 970 |  |  | 1,159 |
Gross deferred tax assets |  | 101,565 |  |  | 96,428 |
Deferred tax liabilities: |  |  |  |
Prepaid expenses |  | — |  |  | — |
Gross deferred tax liabilities |  | — |  |  | — |
Less: valuation allowances |  | (101,565) |  |  | (96,428) |
Net deferred tax assets |  | $ | — |  |  | $ | — |
At December 31, 2024, the Company had $71,588 of net operating losses in Ireland that do not have an expiration date and $227,344 of net operating losses and $5,809 163(j) carryforwards in the U.S. Of the $227,344 of net operating losses in the U.S., $10,365 were acquired due to the acquisition of FSC Therapeutics and FSC Laboratories, Inc., (collectively “FSC”) and $212,637 are due to the losses at US Holdings, of which $4,342 are state net operating losses. The portion due to the acquisition of FSC will expire in 2034 through 2035. The remaining U.S. net operating loss and 163(j) carryforwards do not have an expiration date. A valuation allowance is recorded if, based on the weight of available evidence, it is more likely than not that a deferred tax asset will not be realized. This assessment is based on an evaluation of the level of historical taxable income and projections for future taxable income. For the year ended December 31, 2024, the Company recorded a net increase to the valuation allowance related primarily to current year net operating losses of $5,137. The U.S. net operating losses are subject to an annual limitation as a result of the FSC acquisition under Internal Revenue Code Section 382 and will not be fully utilized before they expire. In addition to net operating losses and 163(j) carryforwards, the Company has U.S. Orphan Drug tax credit carryforwards of $3,059 as well as U.S. Research and Development credits of $1,036. The Orphan Drug Credit and Research and Development credits will expire in 2040 through 2044. The Company's cumulative loss position is significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company has recorded a full valuation allowance on its deferred tax assets. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used. The Company recorded a valuation allowance against all of its net operating losses in Ireland, France and the U.S. as of December 31, 2024 and 2023. The Company intends to continue maintaining a full valuation allowance on the Irish, French and U.S. net operating losses until there is sufficient evidence to support the reversal of all or some portion of these allowances. At December 31, 2024, the Company has unremitted earnings of $3,755 outside of Ireland as measured on a U.S. GAAP basis. Whereas the measure of earnings for purposes of taxation of a distribution may be different for tax purposes, these earnings, which are considered to be invested indefinitely, would become subject to income tax if they were remitted as dividends or if the Company were to sell its stock in the subsidiaries, net of any prior income taxes paid. It is not practicable to estimate the amount of deferred tax liability on such earnings, if any. R&D Tax Credits Receivable The French and Irish governments provide tax credits to companies for spending on innovative R&D. These credits are recorded as an offset of R&D expenses and are credited against income taxes payable in years after being incurred or, if not so utilized, are recoverable in cash after a specified period of time, which may differ depending on the tax credit regime. As of December 31, 2024, the Company’s net research tax credit receivable amounts to $587 and represents an Irish gross research tax credit. As of December 31, 2023, the Company’s net research tax credit receivable amounts to $1,654 and represents a French gross research tax credit of $837 and an Irish gross research tax credit of $817.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration